Clinical trial
An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma
NCT05227144 is registered in ClinicalTrials.gov with ORIC Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- ORIC Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 6, 2022
- Completion date
- March 3, 2025
- Enrollment
- 31 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory multiple myeloma